
Global Biologic Medications for Psoriasis Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Biologic Medications for Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Biologic Medications for Psoriasis market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Biologic Medications for Psoriasis market include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologic Medications for Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologic Medications for Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for Biologic Medications for Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologic Medications for Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biologic Medications for Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biologic Medications for Psoriasis sales, projected growth trends, production technology, application and end-user industry.
Biologic Medications for Psoriasis Segment by Company
AbbVie Biotechnology
Amgen
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Janssen Biotech
Kyowa Kirin
LEO Pharma
Novartis
Ortho Dermatologics
Pfizer
Samsung Bioepis
Tiefenbacher Pharmaceuticals
UCB
Dalian Yawei Pharmaceutical
Hanwha Chemical
China Medical System
Qilu Pharmaceutical
Biologic Medications for Psoriasis Segment by Type
Interleukin Inhibitors
Tyrosine Kinase Inhibitors
Phosphodiesterase Inhibitors
TNF-α Inhibitors
Other
Biologic Medications for Psoriasis Segment by Application
Retail Pharmacies
Hospital and Clinic
Other
Biologic Medications for Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Biologic Medications for Psoriasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biologic Medications for Psoriasis market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologic Medications for Psoriasis significant trends, drivers, influence factors in global and regions.
6. To analyze Biologic Medications for Psoriasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologic Medications for Psoriasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologic Medications for Psoriasis industry.
Chapter 3: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Biologic Medications for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Biologic Medications for Psoriasis in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Biologic Medications for Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Biologic Medications for Psoriasis market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Biologic Medications for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Biologic Medications for Psoriasis market include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologic Medications for Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologic Medications for Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for Biologic Medications for Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologic Medications for Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biologic Medications for Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biologic Medications for Psoriasis sales, projected growth trends, production technology, application and end-user industry.
Biologic Medications for Psoriasis Segment by Company
AbbVie Biotechnology
Amgen
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly
Janssen Biotech
Kyowa Kirin
LEO Pharma
Novartis
Ortho Dermatologics
Pfizer
Samsung Bioepis
Tiefenbacher Pharmaceuticals
UCB
Dalian Yawei Pharmaceutical
Hanwha Chemical
China Medical System
Qilu Pharmaceutical
Biologic Medications for Psoriasis Segment by Type
Interleukin Inhibitors
Tyrosine Kinase Inhibitors
Phosphodiesterase Inhibitors
TNF-α Inhibitors
Other
Biologic Medications for Psoriasis Segment by Application
Retail Pharmacies
Hospital and Clinic
Other
Biologic Medications for Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Biologic Medications for Psoriasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biologic Medications for Psoriasis market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologic Medications for Psoriasis significant trends, drivers, influence factors in global and regions.
6. To analyze Biologic Medications for Psoriasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologic Medications for Psoriasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologic Medications for Psoriasis industry.
Chapter 3: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Biologic Medications for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Biologic Medications for Psoriasis in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
204 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Biologic Medications for Psoriasis Sales Value (2020-2031)
- 1.2.2 Global Biologic Medications for Psoriasis Sales Volume (2020-2031)
- 1.2.3 Global Biologic Medications for Psoriasis Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Biologic Medications for Psoriasis Market Dynamics
- 2.1 Biologic Medications for Psoriasis Industry Trends
- 2.2 Biologic Medications for Psoriasis Industry Drivers
- 2.3 Biologic Medications for Psoriasis Industry Opportunities and Challenges
- 2.4 Biologic Medications for Psoriasis Industry Restraints
- 3 Biologic Medications for Psoriasis Market by Company
- 3.1 Global Biologic Medications for Psoriasis Company Revenue Ranking in 2024
- 3.2 Global Biologic Medications for Psoriasis Revenue by Company (2020-2025)
- 3.3 Global Biologic Medications for Psoriasis Sales Volume by Company (2020-2025)
- 3.4 Global Biologic Medications for Psoriasis Average Price by Company (2020-2025)
- 3.5 Global Biologic Medications for Psoriasis Company Ranking (2023-2025)
- 3.6 Global Biologic Medications for Psoriasis Company Manufacturing Base and Headquarters
- 3.7 Global Biologic Medications for Psoriasis Company Product Type and Application
- 3.8 Global Biologic Medications for Psoriasis Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Biologic Medications for Psoriasis Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Biologic Medications for Psoriasis Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Biologic Medications for Psoriasis Market by Type
- 4.1 Biologic Medications for Psoriasis Type Introduction
- 4.1.1 Interleukin Inhibitors
- 4.1.2 Tyrosine Kinase Inhibitors
- 4.1.3 Phosphodiesterase Inhibitors
- 4.1.4 TNF-α Inhibitors
- 4.1.5 Other
- 4.2 Global Biologic Medications for Psoriasis Sales Volume by Type
- 4.2.1 Global Biologic Medications for Psoriasis Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Biologic Medications for Psoriasis Sales Volume by Type (2020-2031)
- 4.2.3 Global Biologic Medications for Psoriasis Sales Volume Share by Type (2020-2031)
- 4.3 Global Biologic Medications for Psoriasis Sales Value by Type
- 4.3.1 Global Biologic Medications for Psoriasis Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Biologic Medications for Psoriasis Sales Value by Type (2020-2031)
- 4.3.3 Global Biologic Medications for Psoriasis Sales Value Share by Type (2020-2031)
- 5 Biologic Medications for Psoriasis Market by Application
- 5.1 Biologic Medications for Psoriasis Application Introduction
- 5.1.1 Retail Pharmacies
- 5.1.2 Hospital and Clinic
- 5.1.3 Other
- 5.2 Global Biologic Medications for Psoriasis Sales Volume by Application
- 5.2.1 Global Biologic Medications for Psoriasis Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Biologic Medications for Psoriasis Sales Volume by Application (2020-2031)
- 5.2.3 Global Biologic Medications for Psoriasis Sales Volume Share by Application (2020-2031)
- 5.3 Global Biologic Medications for Psoriasis Sales Value by Application
- 5.3.1 Global Biologic Medications for Psoriasis Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Biologic Medications for Psoriasis Sales Value by Application (2020-2031)
- 5.3.3 Global Biologic Medications for Psoriasis Sales Value Share by Application (2020-2031)
- 6 Biologic Medications for Psoriasis Regional Sales and Value Analysis
- 6.1 Global Biologic Medications for Psoriasis Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Biologic Medications for Psoriasis Sales by Region (2020-2031)
- 6.2.1 Global Biologic Medications for Psoriasis Sales by Region: 2020-2025
- 6.2.2 Global Biologic Medications for Psoriasis Sales by Region (2026-2031)
- 6.3 Global Biologic Medications for Psoriasis Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Biologic Medications for Psoriasis Sales Value by Region (2020-2031)
- 6.4.1 Global Biologic Medications for Psoriasis Sales Value by Region: 2020-2025
- 6.4.2 Global Biologic Medications for Psoriasis Sales Value by Region (2026-2031)
- 6.5 Global Biologic Medications for Psoriasis Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Biologic Medications for Psoriasis Sales Value (2020-2031)
- 6.6.2 North America Biologic Medications for Psoriasis Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Biologic Medications for Psoriasis Sales Value (2020-2031)
- 6.7.2 Europe Biologic Medications for Psoriasis Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Biologic Medications for Psoriasis Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Biologic Medications for Psoriasis Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Biologic Medications for Psoriasis Sales Value (2020-2031)
- 6.9.2 South America Biologic Medications for Psoriasis Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Biologic Medications for Psoriasis Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Biologic Medications for Psoriasis Sales Value Share by Country, 2024 VS 2031
- 7 Biologic Medications for Psoriasis Country-level Sales and Value Analysis
- 7.1 Global Biologic Medications for Psoriasis Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Biologic Medications for Psoriasis Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Biologic Medications for Psoriasis Sales by Country (2020-2031)
- 7.3.1 Global Biologic Medications for Psoriasis Sales by Country (2020-2025)
- 7.3.2 Global Biologic Medications for Psoriasis Sales by Country (2026-2031)
- 7.4 Global Biologic Medications for Psoriasis Sales Value by Country (2020-2031)
- 7.4.1 Global Biologic Medications for Psoriasis Sales Value by Country (2020-2025)
- 7.4.2 Global Biologic Medications for Psoriasis Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.9.2 France Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.16.2 China Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.19.2 India Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Biologic Medications for Psoriasis Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Biologic Medications for Psoriasis Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Biologic Medications for Psoriasis Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 AbbVie Biotechnology
- 8.1.1 AbbVie Biotechnology Comapny Information
- 8.1.2 AbbVie Biotechnology Business Overview
- 8.1.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.1.4 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio
- 8.1.5 AbbVie Biotechnology Recent Developments
- 8.2 Amgen
- 8.2.1 Amgen Comapny Information
- 8.2.2 Amgen Business Overview
- 8.2.3 Amgen Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Amgen Biologic Medications for Psoriasis Product Portfolio
- 8.2.5 Amgen Recent Developments
- 8.3 Boehringer Ingelheim Pharmaceuticals
- 8.3.1 Boehringer Ingelheim Pharmaceuticals Comapny Information
- 8.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
- 8.3.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
- 8.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
- 8.4 Bristol-Myers Squibb
- 8.4.1 Bristol-Myers Squibb Comapny Information
- 8.4.2 Bristol-Myers Squibb Business Overview
- 8.4.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio
- 8.4.5 Bristol-Myers Squibb Recent Developments
- 8.5 Eli Lilly
- 8.5.1 Eli Lilly Comapny Information
- 8.5.2 Eli Lilly Business Overview
- 8.5.3 Eli Lilly Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Eli Lilly Biologic Medications for Psoriasis Product Portfolio
- 8.5.5 Eli Lilly Recent Developments
- 8.6 Janssen Biotech
- 8.6.1 Janssen Biotech Comapny Information
- 8.6.2 Janssen Biotech Business Overview
- 8.6.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Janssen Biotech Biologic Medications for Psoriasis Product Portfolio
- 8.6.5 Janssen Biotech Recent Developments
- 8.7 Kyowa Kirin
- 8.7.1 Kyowa Kirin Comapny Information
- 8.7.2 Kyowa Kirin Business Overview
- 8.7.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio
- 8.7.5 Kyowa Kirin Recent Developments
- 8.8 LEO Pharma
- 8.8.1 LEO Pharma Comapny Information
- 8.8.2 LEO Pharma Business Overview
- 8.8.3 LEO Pharma Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.8.4 LEO Pharma Biologic Medications for Psoriasis Product Portfolio
- 8.8.5 LEO Pharma Recent Developments
- 8.9 Novartis
- 8.9.1 Novartis Comapny Information
- 8.9.2 Novartis Business Overview
- 8.9.3 Novartis Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Novartis Biologic Medications for Psoriasis Product Portfolio
- 8.9.5 Novartis Recent Developments
- 8.10 Ortho Dermatologics
- 8.10.1 Ortho Dermatologics Comapny Information
- 8.10.2 Ortho Dermatologics Business Overview
- 8.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio
- 8.10.5 Ortho Dermatologics Recent Developments
- 8.11 Pfizer
- 8.11.1 Pfizer Comapny Information
- 8.11.2 Pfizer Business Overview
- 8.11.3 Pfizer Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Pfizer Biologic Medications for Psoriasis Product Portfolio
- 8.11.5 Pfizer Recent Developments
- 8.12 Samsung Bioepis
- 8.12.1 Samsung Bioepis Comapny Information
- 8.12.2 Samsung Bioepis Business Overview
- 8.12.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio
- 8.12.5 Samsung Bioepis Recent Developments
- 8.13 Tiefenbacher Pharmaceuticals
- 8.13.1 Tiefenbacher Pharmaceuticals Comapny Information
- 8.13.2 Tiefenbacher Pharmaceuticals Business Overview
- 8.13.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
- 8.13.5 Tiefenbacher Pharmaceuticals Recent Developments
- 8.14 UCB
- 8.14.1 UCB Comapny Information
- 8.14.2 UCB Business Overview
- 8.14.3 UCB Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.14.4 UCB Biologic Medications for Psoriasis Product Portfolio
- 8.14.5 UCB Recent Developments
- 8.15 Dalian Yawei Pharmaceutical
- 8.15.1 Dalian Yawei Pharmaceutical Comapny Information
- 8.15.2 Dalian Yawei Pharmaceutical Business Overview
- 8.15.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
- 8.15.5 Dalian Yawei Pharmaceutical Recent Developments
- 8.16 Hanwha Chemical
- 8.16.1 Hanwha Chemical Comapny Information
- 8.16.2 Hanwha Chemical Business Overview
- 8.16.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio
- 8.16.5 Hanwha Chemical Recent Developments
- 8.17 China Medical System
- 8.17.1 China Medical System Comapny Information
- 8.17.2 China Medical System Business Overview
- 8.17.3 China Medical System Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.17.4 China Medical System Biologic Medications for Psoriasis Product Portfolio
- 8.17.5 China Medical System Recent Developments
- 8.18 Qilu Pharmaceutical
- 8.18.1 Qilu Pharmaceutical Comapny Information
- 8.18.2 Qilu Pharmaceutical Business Overview
- 8.18.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Value and Gross Margin (2020-2025)
- 8.18.4 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
- 8.18.5 Qilu Pharmaceutical Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Biologic Medications for Psoriasis Value Chain Analysis
- 9.1.1 Biologic Medications for Psoriasis Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Biologic Medications for Psoriasis Sales Mode & Process
- 9.2 Biologic Medications for Psoriasis Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Biologic Medications for Psoriasis Distributors
- 9.2.3 Biologic Medications for Psoriasis Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.